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Abstract. With the launch of second line anti-retroviral therapy for HIV
infected individuals, there has been an increased expectation on surviving
period of people with HIV. We consider previously well-known models in
epidemiology where the parameter for incubation period is used as one of
the important components to explain the dynamics of the variables. Such
models are extended here to explain the dynamics with respect to a given
therapy that prolongs life of an HIV infected individual. A deconvolution
method is demonstrated for estimation of parameters in the situations when
no-therapy and multiple therapies are given to the infected population. The
models and deconvolution method are extended in order to study the impact
of therapy in age-structured populations. A generalization for a situation
when n−types of therapies are available is given. Models are demonstrated
using hypothetical data and sensitivity of the parameters are also computed.
1. Preliminaries, Basic ODE Model and
Integro-Differential Equations models
With the introduction of second line therapy[53] to the people living with
HIV who were already on first line therapy until introduction of second line
therapy, there is a further hope to increase the active life of HIV infected indi-
viduals. Revised estimates of the people living with HIV are obtained for some
countries to address the impact of second line therapy (see, for example[49]).
Second line theory is provided after failure to responding to the first line
therapy among the infected individuals. Modeling the impact of second line
therapy and corresponding extended survival time is complicated because sus-
ceptible population can acquire virus from two infected class of populations
who are on therapy in addition to the infected population who are without
any therapy. However identifying the first line individuals who are no more
responding to the first line therapy through surveillance is still a challenging
issue in several countries. Difficulties in monitoring and recording HIV in-
fected population who are on first line and second line therapy will also lead
to difficulty in estimating parameters of disease progression and disease re-
lated mortalities. Disease progression rate and incubation period are related
and usually both are taken as reciprocal to each other. Incubation period of
HIV infected individuals is also expected to increase since new anti-retroviral
therapy policies. The incubation period is generally defined as ‘the time du-
ration between the time a virus or bacteria enters the human body and the
time at which clinical clinical symptoms occur’. This duration can vary from
case to case depending upon the route through which the virus or bacteria
enters the immune system of an individual and in some cases depends upon
the age of the infected individual. For chickenpox this duration is 10 - 21 days,
for common cold 2 - 5 days, for mumps 12 to 25 days, for SARS a maximum
of up to 10 days, for rubella 14 - 21 days, for pertussis 7 - 10 days, and for
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HIV infection to AIDS 6 months to 10 years or more. The incubation pe-
riod can be used as a measure of rapidity of the illness after interaction with
the virus or bacteria. It is not easy to collect information on the incubation
period of infected individuals unless they are monitored. One of the direct
ways of estimating the average incubation period of a given virus in the pop-
ulation is by surveillance and followup of the infected individuals until they
develop symptoms. All the infected individuals may not be aware of their
infection until symptoms appear and followup is subject to the availability of
an individual. It might not be possible to follow up individuals in a typical
situation, where time taken for the onset of symptoms from the infection is
longer, especially if infected individuals are lost to followup. Hence, there are
limitations on directly estimating the average incubation period from prospec-
tive cohort studies. Nevertheless, the incubation period occupies an important
role along with other parameters in modeling the disease spread and under-
standing the basic reproductive rate. A useful description of various epidemic
models, and of estimation of parameters like the incubation period, transmis-
sion rates, forces of infections are presented in [3]. The degree of importance
of obtaining accurate average incubation periods varies with the incubation
period of the disease. This degree of variation causes mathematical models
to act sensitively in predicting future burden. Models describing dynamics
of disease spread where the incubation period is shorter are less subject for
producing misleading results than models for the spread with longer and vary-
ing incubation periods. Especially for predicting AIDS, the epidemic models
developed, depend heavily on parameters that determine transmission rates of
infection from infected to susceptible and on the parameter which explains the
average time to progress to AIDS. A review of various modeling approaches
and quantitative techniques to estimate the incubation period can be found
in [8, 6]. The introduction of anti-retroviral therapies and protease inhibitors
during the 1990s in several parts of the world resulted decline in opportunis-
tic infections related to AIDS [41, 9, 11]. As a result of such interventions,
the average incubation period was prolonged. There have been attempts to
estimate the incubation period that vary due to drug intervention using statis-
tical density functions [4]. The impact of this variation on the HIV dynamics,
stability and on basic reproduction number has been investigated [8, 12, 20].
In this section, we first consider an ODE model that explains the dynamics
of HIV spread in a population leading to AIDS (see [13]). We then consider
a similar model where incubation period is a variable with respect to a given
therapy. We address issues of estimating incubation period to be used in such
dynamical models and the impact of above mentioned therapies. Various ideas
and the outline of this work are given at the end of this section.
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Perhaps the most fundamental model for the epidemiology of AIDS is that
given by [13, 2, 3], which takes the form
dX
dt
= Λ− (λ + µ)X,
dY
dt
= λX − (d+ µ) Y,(1.1)
dDz
dt
= dY − γDz.
Here the total population (N) is divided into susceptibles (X), infectives
(Y ) and individuals with the full blown disease (Dz). The parameter Λ is the
input into the susceptible class, which can be defined as the number of births
in the population, λ is the force of infection, µ is general (non-AIDS related)
mortality, γ is disease related mortality and 1/d is the average incubation
period. Here the incubation period is defined as the duration of time between
infection and onset of full blown disease. There are several other constructions
of HIV transmission dynamics models
In the models involving the disease progression parameter, it has been as-
sumed that there is an increase in the mean length of life after HIV infection
since the availability of therapies for AIDS [37, 38]. There are several works
describing the impact of anti-retroviral therapies using data [1, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 39, 40, 41, 43] and through models
[23, 38, 42, 44, 45]. The time to start ART based on the CD4 count is still
debatable. In a recent study on HIV-1 discordant couples [46], it was observed
that the incidence rates among early ART couples are lower than than the inci-
dence rates among couples who were given ART at a standard time. Drugs are
available which cannot eliminate virus from the body, but are helpful in pro-
longing the life of an individual by slowing the disease progression (in other
words increasing the incubation period). For example, protease inhibitors
(say drug 1) facilitate in producing non-infectious virus (only infectious virus
participates in new virus production), hence slowing the disease progression;
anti-retroviral therapy (say drug 2) blocks virus from interacting with the
non-infected cells and hence reduces the infection process within the cell pop-
ulation (see section 5 in [14] and [15] for fuller details); and a combination
of the above two drugs (say drug 3 ) can be more effective by simultaneously
combining the function of drug 1 and drug 2. Note that, when model (1.1)
was developed, the above described drugs were not available. Information on
scale-up of anti-retroviral therapies and related monitoring of individuals can
be found elsewhere (for example, see [23, 50, 47, 51]. We assume that once
individuals start taking drugs, their average incubation period is prolonged.
So, instead of assuming a constant 1/d, we assume that it varies based on the
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drug type. Thus we define 1/di =
∫
R
zig(zi)dzi, for i = 0, 1, 2, 3, where i = 0
denotes the without drug scenario, i = 1 for drug 1, i = 2 for drug 2 and i = 3
for drug 3. Here g is the probability density function with a certain parameter
set (say B) and zi is a continuous random variable representing the incubation
period. Here zi is a real valued function defined on a standard probability
space (S,A, P ), where S is the space of elementary events, A is called a Borel
fields, and P (A) is probability of the event A ∈ A. So, z : S → R. We can also
denote this integral as a Stieltjes integral
∫
R
zidG(zi), where G(z) = P (Z < z).
We further assume without loss of generality that
∫
R
z0dG(z0) <
∫
R
z1dG(z1) ≤ z2dG(z2) <
∫
R
z3dG(z3),(1.2) ∫
R
z0dG(z0) <
∫
R
z1dG(z1) >
∫
R
z2dG(z2) <
∫
R
z3dG(z3).
(In the next section, we will give a detailed estimation procedure for B.)
Applying these varying incubation periods, model (1.1) is modified as follows:
dX
dt
= Λ− (λ0 + λ1 + λ2 + λ3 + µ)X,
dY0
dt
= λ0X −
{(∫
R
z0dG(z0)
)−1
+ µ
}
Y0,
dY1
dt
= λ1X −
{(∫
R
z1dG(z1)
)−1
+ µ
}
Y1,
dY2
dt
= λ2X −
{(∫
R
z2dG(z2)
)−1
+ µ
}
Y2,
dY3
dt
= λ3X −
{(∫
R
z3dG(z3)
)−1
+ µ
}
Y3,
dDz0
dt
=
(∫
R
z0dG(z0)
)−1
Y0 − γ0Dz0,
dDz1
dt
=
(∫
R
z1dG(z1)
)−1
Y1 − γ1Dz1,(1.3)
dDz2
dt
=
(∫
R
z2dF (z2)
)−1
Y2 − γ2Dz2 ,
dDz3
dt
=
(∫
R
z3dG(z3)
)−1
Y3 − γ3Dz3,
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Figure 1.1. Schematic diagram explaining the flow of infected
individuals without therapy to individuals who are on therapy.
where Y0, Y1, Y 2 and Y3 are variables for infectives, Dz0, Dz1 , Dz2 and Dz3
are variables for individuals with the full blown disease, λ0, λ1, λ2 and λ3and
γ0, γ1, γ2 and γ3 are variables for disease related mortality for no-drug, drug
1, drug 2 and drug 3 respectively. See Figure 1.1 describing the flows in the
model eq (1.3). General mortality and disease-related mortality are incorpo-
rated in to the model to demonstrate the basic structure of the model, and our
aim here is to estimate B and thus to estimate
∫
R
zidG(zi) for all i such that
simulations of the model are performed. In model (1.3), the total population
N = X + Y0 + Y1 + Y2 + Y3 +Dz0 +Dz1 +Dz2 +Dz3 satisfies
dN
dt
= Λ− µX + µ
i=3∑
i=0
Yi −
3∑
i=0
γiDzi .
Estimation of parameters for the varying incubation periods is important
for understanding the impact of drugs in prolonging the onset of disease and
thus to prolong the life. The set B will also be useful in obtaining vary-
ing basic reproductive rates, R0i for all i = 0, 1, 2, 3. This can be computed
as R0i = λγi
∫
R
zidG(zi) by assuming independence of the impact of various
drugs. So far, there is no evidence that β, the probability of infecting a suscep-
tible partner changes with the activation of a drug in the body. If we assume
this as a constant, then R00 ≥ R01 ≥ or < R02 ≥ R03. R01 < {R01, R02, R03},
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because individuals are assumed to have longer incubation period due to the ef-
fect of drugs. In the absence of clinical evidence, we assume that the impact of
drug1 and drug2 follows any one of the following relations:
∫
R
z1dG(z1) ≤ or >∫
R
z2dG(z2). Similarly, another important epidemiological measure, the dou-
bling time, tdi is obtained as tdi = ln(2)
∫
R
zidG(zi)/ [R0i − 1] . Anti-retroviral
therapy helps in blocking the virus from interacting with cells and simulta-
neously providing protease inhibitors helps in producing non-infectious virus.
So without loss of generality, it is assumed that the impact of double drug
therapy is better than a single drug therapy. If we assume disease related
mortality is constant for all i then γi = γ. The number of AIDS related deaths
in general are high during latter part of the incubation period due to increase
in opportunistic infections. In general, over all AIDS related mortality rate in
a population is assumed to be higher than the general mortality rate in that
population. Where there are n types of drugs available, we write the general
form for the above dynamical model as follows:
dX
dt
= Λ−
(
n∑
I=0
λi + µ
)
X,
dY0
dt
= λ0X −
{(∫
R
z0dG(z0)
)−1
+ µ
}
Y0,
...
...
...
...
dYn
dt
= λnX −
{(∫
R
zndG(zn)
)−1
+ µ
}
Yn,
dDz0
dt
=
(∫
R
z0dG(z0)
)−1
Y0 − γ0Dz0,
...
...(1.4)
...
...
dDzn
dt
=
(∫
R
zndG(zn)
)−1
Yn − γnDzn,
As a special case we can consider all the parameters in the above model
as Stieltjes integrals and can estimate them using the rigorous procedure ex-
plained in the next section. For n = 3 in the model (1.4), we can deduce the
model (1.3). Practically, we do not have a situation where several drugs are
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available in the market for HIV infected individuals. Hence, the model (1.4)
should be treated as a theoretical generalization.
This paper is organized as follows: In section 2, we present contemporary
models constructed for understanding transmission dynamics of HIV for policy
formulations and corresponding modified disease progression component that
captures the impact of therapy, in section 3, we describe in detail the esti-
mation of the set B for up to three drugs; section 4 gives the corresponding
expressions for the conditional probabilities of N−drugs. We construct the-
oretical examples using three functions: Gamma, Logistic and Log-normal in
section 5 to demonstrate the method explained in section 3. In section 6 anal-
ysis for age-structured populations is described in detail. Overall conclusions
are given in section 7. Appendix I gives equations for conditional probability
when incubation period for various drug types does not have the monotonicity
property. Appendix II gives some more theoretical examples when the incuba-
tion period is truncated to the right. Appendix III provides parameter values
adopted for numerical simulations and Appendix IV has numerical demonstra-
tion of the model outputs and sensitivity of parameters in projecting HIV and
AIDS.
2. Contemporary models and Modifications
In this section, we present a contemporary model for HIV epidemic in India
[19] and corresponding integro-differential equations. HIV model [19] devel-
oped based on Indian data has three components, 1) Model for spread in
general population, 2) model for spread in homosexual men (MSM), 3) model
for spread in intravenous drug users (IDU). We provide a description of this
model and then write corresponding revised model with integro differential
equations. The system of differential equations in three models have incorpo-
rated dynamics in fourteen compartments: U(i), susceptible population; V (i),
sexually transmitted diseases population; W (i), HIV infected; T (i), AIDS in
the general population for gender i (say, i = 1 for male and i = 2 for female),
U(m), susceptible MSM; V (m), sexually transmitted infected MSM;, W (m),
HIV infected MSM; T (m), MSM population with AIDS; U(IDU), suscepti-
ble intravenous drug users; W (IDU), HIV infected intravenous drug users;
T (IDU), intravenous drug users with AIDS. Male susceptible in general pop-
ulation is eligible to acquire virus from j th sub-population (j = 1, female
married partner; j = 2, female casual partner, j = 3, commercial sex worker;
j = 4, through blood transfusions. All the sub-populations are allowed to
contribute for the transmission dynamics of HIV and each sub-population is
also subject to the risk of acquiring the infection from other sub-population
wherever applicable (see [19] for complete description).
The differential equations describing the Indian HIV epidemic model are
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General
Model


dU(i)
dt
= aiU(i)− U(i)
(∑4
j=1
bijV (i)
N(j)
+
∑4
j=1
cijW (j)
N(j)
)
+ φV (i)
dV (i)
dt
= U(i)
∑4
j=1
bijV (i)
N(j)
− V (i)∑4j=1 dijW (j)N(j) − µV (i)− φV (i)
dW (i)
dt
= U(i)
∑4
j=1
cijW (j)
N(j)
+ V (i)
∑4
j=1
dijW (j)
N(j)
−
δiW (i)− αiW (i)
dT (i)
dt
= αiW (i)− µiT (i)
MSM
Model


dU(m)
dt
= amU(m)− U(m)
(
bmV (m)
N(m)
+ cmW (m)
N(m)
)
+ φV (m)
dV (m)
dt
= U(m) bmV (m)
N(m)
− V (m)dmW (m)
N(m)
− µV (m)− φV (m)
dW (m)
dt
= U(m) cmW (m)
N(m)
+ V (m)dmW (m)
N(m)
−
δmW (m)− αmW (m)
dT (m)
dt
= αmW (m)− µmT (m)
IDU
Model


dU(IDU)
dt
= aIDUU(IDU)− U(IDU)
(
cIDUW (IDU)
N(IDU)
)
+
φV (IDU)
dW (IDU)
dt
= U(IDU) cIDUW (IDU)
N(IDU)
− δIDUW (IDU)−
αIDUW (IDU)
dT (IDU)
dt
= αIDUT (IDU)− µIDUT (IDU)
where, N(j) = V (j) +W (j) for j = 1, 2, 3, 4 and N(m) = V (m) +W (m)
The corresponding models with flexible incubation periods are
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dU(i)
dt
= aiU(i)− U(i)
(
4∑
j=1
bijV (i)
N(j)
+
3∑
k=0
4∑
j=1
cijkW (j)
N(j)
)
+ φV (i)
dV (i)
dt
= U(i)
4∑
j=1
bijV (i)
N(j)
− V (i)
3∑
k=0
4∑
j=1
dijkW (j)
N(j)
− µV (i)− φV (i)
dW0(i)
dt
= U(i)
4∑
j=1
cij0W (j)
N(j)
+ V (i)
4∑
j=1
dij0W (j)
N(j)
−
{(∫
R
z0dG(z0)
)−1
+ δi
}
W0(i)
dW1(i)
dt
= U(i)
4∑
j=1
cij1W (j)
N(j)
+ V (i)
4∑
j=1
dij1W (j)
N(j)
−
{(∫
R
z1dG(z1)
)−1
+ δi
}
W1(i)
dW2(i)
dt
= U(i)
4∑
j=1
cij2W (j)
N(j)
+ V (i)
4∑
j=1
dij2W (j)
N(j)
−
{(∫
R
z2dG(z2)
)−1
+ δi
}
W2(i)
dW3(i)
dt
= U(i)
4∑
j=1
cij3W (j)
N(j)
+ V (i)
4∑
j=1
dij3W (j)
N(j)
−
{(∫
R
z3dG(z3)
)−1
+ δi
}
W3(i)
dTz0(i)
dt
=
(∫
R
z0dG(z0)
)−1
W0(i)− µ0Tzo
dTz1(i)
dt
=
(∫
R
z1dG(z1)
)−1
W1(i)− µ1Tz1
dTz2(i)
dt
=
(∫
R
z2dG(z2)
)−1
W2(i)− µ1Tz1
dTz3(i)
dt
=
(∫
R
z3dG(z3)
)−1
W3(i)− µ3Tz3
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dU(m)
dt
= amU(m)− U(m)
(
bmV (m)
N(m)
+
3∑
k=0
cmW (m)
N(m)
)
+ φV (m)
dV (m)
dt
= U(m)
bmV (m)
N(m)
− V (m)
3∑
k=0
dmW (m)
N(m)
− µV (m)− φV (m)
dW0(m)
dt
= U(m)
cm0W (m)
N(m)
+ V (m)
dm0W (m)
N(m)
−{(∫
R
z0dG(z0)
)−1
+ δm
}
W0(m)
dW1(m)
dt
= U(m)
cm1W (m)
N(m)
+ V (m)
dm1W (m)
N(m)
−{(∫
R
z1dG(z1)
)−1
+ δm
}
W1(m)
dW2(m)
dt
= U(m)
cm2W (m)
N(m)
+ V (m)
dm2W (m)
N(m)
−{(∫
R
z2dG(z2)
)−1
+ δm
}
W2(m)
dW3(m)
dt
= U(m)
cm3W (m)
N(m)
+ V (m)
dm3W (m)
N(m)
−{(∫
R
z0dG(z0)
)−1
+ δm
}
W3(m)
dTz0(m)
dt
=
(∫
R
z0dG(z0)
)−1
W0(m)− µmTz0(m)
dTz1(m)
dt
=
(∫
R
z1dG(z1)
)−1
W1(m)− µmTz1(m)
dTz2(m)
dt
=
(∫
R
z2dG(z2)
)−1
W2(m)− µmTz2(m)
dTz3(m)
dt
=
(∫
R
z3dG(z3)
)−1
W3(m)− µmTz3(m)
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dU(IDU)
dt
= aIDUU(IDU)− U(IDU)
3∑
k=0
(
cIDU,kW (IDU)
N(IDU)
)
+ φV (IDU)
dW0(IDU)
dt
= U(IDU)
(
cIDU,0W (IDU)
N(IDU)
)
−{(∫
R
z0dG(z0)
)−1
+ δIDU
}
W0(IDU)
dW1(IDU)
dt
= U(IDU)
(
cIDU,1W (IDU)
N(IDU)
)
−{(∫
R
z1dG(z1)
)−1
+ δIDU
}
W1(IDU)
dW2(IDU)
dt
= U(IDU)
(
cIDU,2W (IDU)
N(IDU)
)
−{(∫
R
z2dG(z2)
)−1
+ δIDU
}
W2(IDU)
dW3(IDU)
dt
= U(IDU)
(
cIDU,3W (IDU)
N(IDU)
)
−{(∫
R
z3dG(z3)
)−1
+ δIDU
}
W3(IDU)
dTz0(IDU)
dt
=
(∫
R
z0dG(z0)
)−1
W0(IDU)− µIDUTz0(IDU)
dTz1(IDU)
dt
=
(∫
R
z1dG(z1)
)−1
W1(IDU)− µIDUTz1(IDU)
dTz2(IDU)
dt
=
(∫
R
z2dG(z2)
)−1
W2(IDU)− µIDUTz2(IDU)
dTz3(IDU)
dt
=
(∫
R
z3dG(z3)
)−1
W3(IDU)− µIDUTz3(IDU)
where the variables with suffix z0, z2, z3, z3 are corresponding to the im-
pact drug0, drug1, drug2, drug3 respectively. These contemporary models
are improvised version of basic models presented in section 1 and are tested
to predict accurately the epidemic situation during the era of anti-retroviral
therapies.
INCUBATION PERIOD, ANTI-RETROVIRAL THERAPIES, AGE-STRUCTURES 14
3. Conditional probabilities
In this section, we will give a detailed procedure to estimate B through a
deconvolution technique. Let B be split into a collection of four parameter
sets say, B={B0, B1, B2, B3} for the four types of scenarios described in the
previous section. Let H be the time of infection and Z be the incubation
period, then the time of onset of the disease can be represented as D = H+Z.
There have been studies (see for list of references Brookmeyer and Gail (1994)),
in which H and Z were assumed independent and D was estimated through
convolution. We outline the general idea of convolution and then give the
convolution of H and Z. Suppose (an) and (bn) are two sequences of numbers
over the time period, then
(an) ∗ (bn) =
n∑
k=0
anbn−k(3.1)
where (an) ∗ (bn) is the convolution of these sequences with an operator ′∗′.
Suppose a and b are mutually independent random variables and let AL(x)
and BL(x) be their Laplace transformations, then a+ b has the Laplace trans-
formation ALBL. Since the multiplication of the Laplace transformation is
associative and commutative, it follows that (an) ∗ (bn) is also associative and
commutative. Instead of discrete notation, suppose a and b are continuous
and independent with probability density functions h and g, then the density
of h+ g is given by
f(s) =
∫ ∞
−∞
h(t− s)g(t)dt =
∫ ∞
−∞
h(t)g(t− s)ds
.
Suppose G(s) =
∫ s
−∞ g(s)ds, and F (s) =
∫ s
−∞ f(s)ds then
F (s) =
∫ ∞
−∞
h(t)G(t− s)ds.(3.2)
We call F the convolution of h and G. Suppose the above h and G represent
the infection density and incubation period distribution function; then the
convolution of h and G represents the cumulative number of disease cases
reported (or observed), and is given by
h ∗G =
∫ ∞
−∞
h(t)G(t− s)ds.(3.3)
This kind of convolution in (3.3) was used to estimate the number of AIDS
cases for the first time by [7]. Information on G may not be available for some
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populations. In such situations, G has been estimated through deconvolution
from the information available on h ∗G and h [16, 17]. In this section we will
construct conditional probabilities for each drug type and express the function
that maximizes B. These kind of conditional probabilities derived for the
drug type were not available earlier for the incubation periods when the total
number of reported disease cases were considered. Note that h ∗ G is the
cumulative number of disease cases.
Let X0, X1, X2, ..., Xn−k, ..., Xn−l, ..., Xn−m, ..., Xn be the disease cases avail-
able in the time intervals [Ui−1, Ui) for i = 0, 1, 2, ...n− k, ...n− l, ...(n−m) +
1, ...n+1. Suppose E is the event of diagnosis of disease after the first infection
at T0. Let E = {E0, E1, E2, E3} and E0 occurs in the interval [U0, Un−k), E1
(or E2) in [Un−k, Un−l) (or [Un−l, Un−m)) and E3 in [Un−m, Un). Now D, the
cumulative number of disease cases up to time Un, can be expressed from (3.3)
as follows:
D (U0 ≤ s ≤ Un) =
∫ Un−k
0
h(t)G(t− s)ds+
∫ Un−l
Un−k
h(t)G(t− s)ds
+
∫ Un−m
Un−l
h(t)G(t− s)ds+
∫ Un
Un−m
h(t)G(t− s)ds,(3.4)
D (A,B/Un) =
∫ Un−k
0
h(t/A0)G(t− s/B0)ds+
∫ Un−l
Un−k
h(t/A1)G(t− s/B1)ds
+
∫ Un−m
Un−l
h(t/A2)G(t− s/B2)ds+
∫ Un
Un−m
h(t/A3)G(t− s/B3)ds.
In the above equation A0,A1, A2 and A3 are the parameter sets for the h for
drug0, drug1, drug2 and drug3. An infected individual could fall in to any
of the intervals described above, and similarly a full-blown disease diagnosed
individual could fall in the same interval, but for a given individual the chrono-
logical time of infection would be earlier than that of diagnosis of the disease.
Un−k is the time of introduction of drugs after infection at U0. Individuals
who were diagnosed on or after Un−k, and before Un, were taking one of the
three drugs. If E1 ∈ [Un−k, Un−l) and E2 ∈ [Un−l, Un−m) Z1 < Z2, otherwise
if E1 ∈ [Un−l, Un−m) and E2 ∈ [Un−k, Un−l) then and if E1, E2 ∈ [Un−k, Un−m)
then Z1 = Z2. An individual who was diagnosed with the disease before
Un must have developed symptoms in one of the four intervals [U0, Un−k),
[Un−k, Un−l), [Un−l, Un−m) and [Un−m, Un). Let Ej ∈ [Uj−1, Uj) ⊆ [U0, Un−k),
then the conditional probability of the occurrence of Ej given E is expressed
as
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P (Ej/E) = P (Uj−1 ≤ D ≤ Uj/D ≤ Un)
=
D (A0, B0/Uj)−D (A0, B0/Uj−1)
D (A0, B0/Un)
=
∫ Uj
0
h(t/A0)G(t− s/B0)ds.
[∫ Un
0
h(t/A0)G(t− s/B0)ds
]−1
−
∫ Uj−1
0
h(t/A0)G(t− s/B0)ds.
[∫ Un
0
h(t/A0)G(t− s/B0)ds
]−1
.(3.5)
If drugs were initiated at Un−k, then these conditional probabilities con-
structed above will change according to the occurrence of E1, E2, E3. Consider
E1 ∩ E2 = ∅. Let Ek ∈ [Uk−1, Uk) ⊆ [Un−k, Un−l), and E1 ∈ [Un−k, Un−l), then
P (Ek/E) = P (Uk−1 ≤ D ≤ Uk/D ≤ Un)
=
D (A1, B1/Uk)−D (A1, B1/Uk−1)
D (A1, B1/Un)
=
∫ Uk
0
h(t/A1)G(t− s/B1)ds.
[∫ Un
0
h(t/A1)G(t− s/B1)ds
]−1
−
∫ Uk−1
0
h(t/A1)G(t− s/B1)ds.
[∫ Un
0
h(t/A1)G(t− s/B1)ds
]
.−1(3.6)
Suppose Ek ∈ [Uk−1, Uk) ⊆ [Un−k, Un−l), and E2 ∈ [Un−k, Un−l) i.e a situa-
tion when Z1 > Z2, then
P (Ek/E) =
∫ Uk
0
h(t/A2)G(t− s/B2)ds.
[∫ Un
0
h(t/A2)G(t− s/B2)ds
]−1
−
∫ Uk−1
0
h(t/A2)G(t− s/B2)ds.
[∫ Un
0
h(t/A2)G(t− s/B2)ds
]−1
.(3.7)
Let El ∈ [Ul−1, Ul) ⊆ [Un−l, Un−m), and E2 ∈ [Un−l, Un−m), then
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P (El/E) = P (Ul−1 ≤ D ≤ Ul/D ≤ Un)
=
D (A2, B2/Ul)−D (A2, B2/Ul−1)
D (A2, B2/Un)
=
∫ Ul
0
h(t/A2)G(t− s/B2)ds.
[∫ Un
0
h(t/A2)G(t− s/B2)ds
]−1
−
∫ Ul−1
0
h(t/A2)G(t− s/B2)ds.
[∫ Un
0
h(t/A2)G(t− s/B2)ds
]
.−1(3.8)
Suppose El ∈ [Ul−1, Ul) ⊆ [Un−l, Un−m), and E1 ∈ [Un−l, Un−m) i.e a situa-
tion when Z1 > Z2, then
P (El/E) =
∫ Ul
0
h(t/A1)G(t− s/B1)ds.
[∫ Un
0
h(t/A1)G(t− s/B1)ds
]−1
−
∫ Ul−1
0
h(t/A1)G(t− s/B1)ds.
[∫ Un
0
h(t/A1)G(t− s/B1)ds
]−1
.(3.9)
Now consider E1 = E2 ∈ [Up−1, Up) ⊆ [Un−k, Un−m), i.e. Z1 = Z2, then the
conditional probabilities contain the same parameter sets. In this situation,
P (Ep/E) =
∫ Up
0
h(t/A1)G(t− s/B1)ds.
[∫ Un
0
h(t/A1)G(t− s/B1)ds
]−1
−
∫ Up−1
0
h(t/A1)G(t− s/B1)ds.
[∫ Un
0
h(t/A1)G(t− s/B1)ds
]−1
.(3.10)
Since Z3 > Z0, Z1, Z2, suppose E3 ∈ [Um−1, Um) ⊆ [Un−m, Un], then
P (Um−1 ≤ D ≤ Um/D ≤ Un) = D (A3, B3/Um)−D (A3, B3/Um−1)
D (A3, B3/Un)
.
Therefore,
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P (Em/E) =
∫ Um
0
h(t/A3)G(t− s/B3)ds.
[∫ Un
0
h(t/A3)G(t− s/B3)ds
]−1
−
∫ Um−1
0
h(t/A3)G(t− s/B3)ds.
[∫ Un
0
h(t/A3)G(t− s/B3)ds
]−1
(3.11)
The above conditional probabilities P (Ej/E) , P (Ek/E) , P (El/E) , P (Ep/E)
and P (Em/E) are the probabilities associated with the intervals [Uj′−1, Uj′)
, [Uk′−1, Uk′), [Ul′−1, Ul′), [Up′−1, Up′) and [Um′−1, Um′) for the ranges of j, k, l, p
and m defined above. Since, X0, X1, X2, ..., Xn−k, ...,Xn−l, ..., Xn−m, ..., Xn are
mutually exclusive, we assume they follow a parametric distribution with the
above probabilities are mutually exclusive, so we assume they follow the multi-
nomial property of the distribution of the values in the time intervals and the
above conditional probabilities. Then the likelihood functions corresponding
to the event set E are L0 (A,B/Pj) =
∏n−k
j′=1 Pj (A,B/Tj′), L1(2) (A,B/Pk) =∏n−l
k′=n−kPk′ (A,B/Tk′), L2(1) (A,B/Pl′) =
∏n−m
l′=n−l Pl′ (A,B/Tl′), L1=2 (A,B/Pp)
=
∏n−m
p′=n−k Pp′ (A,B/Tp′) and L3 (A,B/Pm) =
∏n
m′=n−m Pm′ (A,B/Tm′) .
Here P• = P (E•/E). We estimate A by fitting an infection curve from the
incidence data and we then estimate B by maximizing the likelihood func-
tions expressed above. The best estimate of A could be information for initial
values of X and Y in the model (1.3). Using the corresponding estimate
of B, we obtain
∫
R
zidF (zi). In such situations, the above likelihood func-
tions would be L0 =
∏n−k
j′=0 P
Tj′
j , L1(2) =
∏n−l
k′=n−k P
Tk′
k ,L2(1) =
∏n−m
l′=n−l P
Tl′
l ,
L1=2 =
∏n−m
p′=n−k P
Tp′
p and L3 =
∏n
m′=n−m P
Tm′
m .
4. Generalization for multiple drug impact
In this section, expressions for the conditional probabilities are presented
when multiple drugs are administrated in the population. Refer to the sec-
tions 2 and 3 for introduction on the role of various drugs and refer to the
section 4 for basic formulations of conditional probabilities when there are
three types of drugs to prolong the incubation period and without any drug
situation that would not alter natural process of disease progression. Modeling
for the situation corresponding to no drug is highly relevant for those countries
where surveillance and diagnosis of infections are not complete and several in-
dividuals with HIV are not taking drugs. LetN = {N0, N1, N2, ..., NN} be the
number of available drugs and Z = {Z0, Z1, Z2, ..., ZN} be their corresponding
incubation periods. Further let Z0 < Z1 < Z2 <, ..., < ZN and A and B be
their parametric sets. Then
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D (A,B/UNN ) =
∫ UN0
0
h(t/AN0)G(t− s/BN0)ds
+
∫ UN1
UN0
h(t/AN1)G(t− s/BN1)ds
· · ·+
∫ UNN
UNN−1
h(t/ANN )G(t− s/BNN )ds.(4.1)
Now, P (ENi/E) = P
(
UNi−1 ≤ D ≤ UNi/D ≤ UNN
)
and LNi (for some i)
can be computed as follows:
P (ENi/E) =
∫ UNi
0
h(t/ANi)G(t− s/BNi)ds×
[∫ UNN
0
h(t/ANN )G(t− s/BNN )ds
]−1
−
∫ UNi−1
0
h(t/ANi−1)G(t− s/BNi−1)ds×
[∫ UNN
0
h(t/ANN )G(t− s/BNN )ds
]
.−1(4.2)
LNi =
∏Ni
j=Ni−1
P
Tj
j is maximized for the set [Ai, Bi] by the procedure ex-
plained in the previous section. We will obtain N sets of [A,B] values, and
the corresponding likelihood values are LN1 , LN2 , LN3 , ..., LNN . In the above,
we have assumed monotonicity of (Zi) to arrive at (4.2). If the (Zi) val-
ues are not monotonic then the various conditional probabilities can be con-
structed as explained in the previous section. There we explained the general
expression when there were a finite number of drugs available on the market.
A detailed construction of various conditional probabilities is not necessary
for the purpose of the present section (for details see Appendix I). When
the Zis are not monotonic, and if they follow some order, say for example,
Z0 > Z1 < Z2 > ... < ZN , then the conditional probabilities can be con-
structed in the same way as equations (3.7e3.9) were. Suppose (Zp) are equal
for each p, then there will be two scenarios arising: one for before drug in-
tervention and one after drug intervention. For this situation, the likelihood
equation is LNp =
∏Np
p=Np−1
P
Tp
p where P
(
ENp/E
)
, is given as follows:
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P
(
ENp/E
)
=
∫ UNp
0
h(t/ANp)G(t− s/BNp)ds×
[∫ UNN
0
h(t/ANN )G(t− s/BNN )ds
]−1
−
∫ UNp−1
0
h(t/ANp−1)G(t− s/BNp−1)ds×
[∫ UNN
0
h(t/ANN )G(t− s/BNN )ds
]
.(4.3)
5. Theoretical examples
In this section, we show some examples of the likelihood function constructed
in the previous section, to estimate A, and B. Let h(s) follow a quadratic
exponential and B follow a) a gamma function, and b) a logistic function.
Infections in most of the countries started declining after the availability of
antiretroviral therapies [9, 11], and incidence in the recent period was found
to be stable in some countries like India [19]. This motivated us to choose a
quadratic exponential to represent h(s), namely h(s) = exp(α1s
2+α2s+α3) for
all −∞ < α1, α2, α3 < ∞. A quadratic exponential function has been shown
to be a good model for representing the above declines in the incidence rates
[17]. The incubation period for AIDS is large as well as variable, therefore,
functions like the gamma, Weibull and logistic can mimic several shapes to fit
the incubation period data depending on their parameter values. Such well-
known functions were used by many researchers for modeling the incubation
period of AIDS. We now demonstrate the application of such functions for the
theory explained in section 2.
5.1. Example 1: Gamma function. If ω > 0 is the parameter and Γ(ω)
is the complete distribution function, then the incomplete gamma distribu-
tion, G(ω; tj) =
1
Γ(ω)
∫ tj
0
e−xxω−1dx, for a ≥ 0, tj ≥ 0 and a+ tj 6= 0. From the
conditional probability equations from (3.5) to (3.11), and the likelihood equa-
tions explained in the later part of section 3, the following are the likelihood
equations without a drug and for with three types of drugs:
L0 (α1, α2, α3;ω/Pj) =
∏
j
a1(j)a2(j)−
∏
j
a1(j − 1)a2(j)(5.1)
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where
a1(j) =
[∫ uj
0
eα1s
2+α2s+α3
{
1
Γω
∫ tj
0
e−(uj−s)(uj − s)ω−1duj
}
ds
]Tj
a1(j − 1) =
[∫ uj−1
0
eα1s
2+α2s+α3
×
{
1
Γω
∫ tj−1
0
e−(uj−1−s)(uj−1 − s)ω−1duj−1
}
ds
]Tj
a2(j) =
[∫ un
0
eα1s
2+α2s+α3
{
1
Γω
∫ tn
0
e−(un−s)(un − s)ω−1dun
}
ds
]−Tj
L1(2) (α1, α2, α3;ω/Pk) =
∏
k
a1(k)a2(k)−
∏
k
a1(k − 1)a2(k)(5.2)
where
a1(k) =
[∫ uk
0
eα1s
2+α2s+α3
{
1
Γω
∫ tk
0
e−(uk−s)(uk − s)ω−1duk
}
ds
]Tk
a1(k − 1) =
[∫ uk−1
0
eα1s
2+α2s+α3
×
{
1
Γω
∫ tk−1
0
e−(uk−1−s)(uk−1 − s)ω−1duk−1
}
ds
]Tk
a2(k) =
[∫ un
0
eα1s
2+α2s+α3
{
1
Γω
∫ tn
0
e−(un−s)(un − s)ω−1dun
}
ds
]−Tk
L2(1) (α1, α2, α3;ω/Pl) =
∏
l
a1(l)a2(l)−
∏
l
a1(l − 1)a2(l)(5.3)
where
INCUBATION PERIOD, ANTI-RETROVIRAL THERAPIES, AGE-STRUCTURES 22
a1(l) =
[∫ ul
0
eα1s
2+α2s+α3
{
1
Γω
∫ tl
0
e−(ul−s)(ul − s)ω−1dul
}
ds
]Tl
a1(l − 1) =
[∫ ul−1
0
eα1s
2+α2s+α3
×
{
1
Γω
∫ tl−1
0
e−(ul−1−s)(ul−1 − s)ω−1dul−1
}
ds
]Tl
a2(l) =
[∫ un
0
eα1s
2+α2s+α3
{
1
Γω
∫ tn
0
e−(un−s)(un − s)ω−1dun
}
ds
]−Tl
L1=2 (α1, α2, α3;ω/Pp) =
∏
p
a1(p)a2(p)−
∏
p
a1(p− 1)a2(p)(5.4)
where
a1(p) =
[∫ up
0
eα1s
2+α2s+α3
{
1
Γω
∫ tp
0
e−(up−s)(up − s)ω−1dup
}
ds
]Tp
a1(p− 1) =
[∫ up−1
0
eα1s
2+α2s+α3
×
{
1
Γω
∫ tp−1
0
e−(up−1−s)(up−1 − s)ω−1dup−1
}
ds
]Tp
a2(p) =
[∫ un
0
eα1s
2+α2s+α3
{
1
Γω
∫ tn
0
e−(un−s)(un − s)ω−1dun
}
ds
]−Tp
L3 (α1, α2, α3;ω/Pm) =
∏
m
a1(m)a2(m)−
∏
m
a1(m− 1)a2(m)(5.5)
where
INCUBATION PERIOD, ANTI-RETROVIRAL THERAPIES, AGE-STRUCTURES 23
a1(m) =
[∫ um
0
eα1s
2+α2s+α3
{
1
Γω
∫ tm
0
e−(um−s)(um − s)ω−1dum
}
ds
]Tm
a1(m− 1) =
[∫ um−1
0
eα1s
2+α2s+α3
×
{
1
Γω
∫ tm−1
0
e−(um−1−s)(um−1 − s)ω−1dum−1
}
ds
]Tm
a2(m) =
[∫ un
0
eα1s
2+α2s+α3
{
1
Γω
∫ tn
0
e−(un−s)(un − s)ω−1dun
}
ds
]−Tm
5.2. Example 2: Logistic function. Suppose θ1, θ2 are parameters and
F (θ1, θ2; tj) =
{
1 + e
−( tj−θ1
θ2
)
}−1
, for θ1, θ2 > 0, is the distribution function.
The likelihood equations to obtain the parameters of logistic distribution with-
out drugs and for three types of drugs are as follows:
L0 (α1, α2, α3; θ1, θ2/Pj) =
∏
j
a′1(j)a
′
2(j)−
∏
j
a′1(j − 1)a′2(j)(5.6)
where
a′1(j) =
[∫ uj
0
eα1s
2+α2s+α3
{{
1 + e
−(uj−θ1
θ2
)
}−1}
ds
]Tj
a′1(j − 1) =
[∫ uj−1
0
eα1s
2+α2s+α3
{{
1 + e
−(uj−1−θ1
θ2
)
}−1}
ds
]Tj
a′2(j) =
[∫ un
0
eα1s
2+α2s+α3
{{
1 + e
−(un−θ1
θ2
)
}−1}
ds
]−Tj
L1(2) (α1, α2, α3; θ1, θ2/Pk) =
∏
k
a′1(k)a
′
2(k)−
∏
k
a′1(k − 1)a′2(k)(5.7)
where
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a′1(k) =
[∫ uk
0
eα1s
2+α2s+α3
{{
1 + e
−(uk−θ1
θ2
)
}−1}
ds
]Tk
a′1(k − 1) =
[∫ uk−1
0
eα1s
2+α2s+α3
{{
1 + e
−(uk−1−θ1
θ2
)
}−1}
ds
]Tk
a′2(k) =
[∫ un
0
eα1s
2+α2s+α3
{{
1 + e
−(un−θ1
θ2
)
}−1}
ds
]−Tk
L2(1) (α1, α2, α3; θ1, θ2/Pl) =
∏
l
a′1(l)a
′
2(l)−
∏
l
a′1(l − 1)a′2(l)(5.8)
where
a′1(l) =
[∫ ul
0
eα1s
2+α2s+α3
{{
1 + e
−(ul−θ1
θ2
)
}−1}
ds
]Tl
a′1(l − 1) =
[∫ ul−1
0
eα1s
2+α2s+α3
{{
1 + e
−(ul−1−θ1
θ2
)
}−1}
ds
]Tl
a′2(l) =
[∫ un
0
eα1s
2+α2s+α3
{{
1 + e
−(un−θ1
θ2
)
}−1}
ds
]−Tl
L1=2 (α1, α2, α3; θ1, θ2/Pp) =
∏
p
a′1(p)a
′
2(p)−
∏
p
a′1(p− 1)a′2(p)(5.9)
where
a′1(p) =
[∫ up
0
eα1s
2+α2s+α3
{{
1 + e
−(up−θ1
θ2
)
}−1}
ds
]Tp
a′1(p− 1) =
[∫ up−1
0
eα1s
2+α2s+α3
{{
1 + e
−(up−1−θ1
θ2
)
}−1}
ds
]Tp
a′2(p) =
[∫ un
0
eα1s
2+α2s+α3
{{
1 + e
−(un−θ1
θ2
)
}−1}
ds
]−Tp
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L3 (α1, α2, α3; θ1, θ2/Pm) =
∏
m
a′1(m)a
′
2(m)−
∏
m
a′1(m− 1)a2(m)(5.10)
where
a′1(m) =
[∫ um
0
eα1s
2+α2s+α3
{{
1 + e
−(um−θ1
θ2
)
}−1}
ds
]Tm
a′1(m− 1) =
[∫ um−1
0
eα1s
2+α2s+α3
{{
1 + e
−(um−1−θ1
θ2
)
}−1}
ds
]Tm
a′2(m) =
[∫ un
0
eα1s
2+α2s+α3
{{
1 + e
−(un−θ1
θ2
)
}−1}
ds
]−Tm
5.3. Example 3: Log-normal function. Suppose µ and σ are parameters
and LNF (µ, σ; tj) =
1
2
{
1 + erf
(
lnx−µ
σ
√
2
)}
, for µ, σ > 0, is the distribution
function. (Here erf{.} is the error function of the Gaussian function). The
likelihood equations to obtain the parameters of the logistic distribution with-
out drugs and for three types of drugs are as follows:
L0 (α1, α2, α3;µ, σ/Pj) =
∏
j
a′′1(j)a
′′
2(j)−
∏
j
a′′1(j − 1)a′′2(j)(5.11)
where
a′′1(j) =
[
1
2
∫ uj
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]Tj
a′′1(j − 1) =
[
1
2
∫ uj−1
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]Tj
a′′2(j) =
[
1
2
∫ un
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]−Tj
L1(2) (α1, α2, α3;µ, σ/Pk) =
∏
k
a′′1(k)a
′′
2(k)−
∏
k
a′′1(k − 1)a′′2(k)(5.12)
where
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a′′1(k) =
[
1
2
∫ uk
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]Tk
a′′1(k − 1) =
[
1
2
∫ uk−1
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]Tk
a′′2(k) =
[
1
2
∫ un
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]−Tk
L2(1) (α1, α2, α3;µ, σ/Pl) =
∏
l
a′′1(l)a
′′
2(l)−
∏
l
a′′1(l − 1)a′′2(l)(5.13)
where
a′′1(l) =
[
1
2
∫ ul
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]Tl
a′′1(l − 1) =
[
1
2
∫ ul−1
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]Tl
a′′2(l) =
[
1
2
∫ un
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]−Tl
L1=2 (α1, α2, α3;µ, σ/Pp) =
∏
p
a′′1(p)a
′′
2(p)−
∏
p
a′′1(p− 1)a′′2(p)(5.14)
where
a′′1(p) =
[
1
2
∫ up
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]Tp
a′′1(p− 1) =
[
1
2
∫ up−1
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]Tp
a′′2(p) =
[
1
2
∫ un
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]−Tp
L3 (α1, α2, α3;µ, σ/Pm) =
∏
m
a′1(m)a
′
2(m)−
∏
m
a′1(m− 1)a2(m)(5.15)
where
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a′′1(m) =
[
1
2
∫ um
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]Tm
a′′1(m− 1) =
[
1
2
∫ um−1
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]Tm
a′′2(m) =
[
1
2
∫ un
0
eα1s
2+α2s+α3
{
1 + erf
(
ln x− µ
σ
√
2
)}
ds
]−Tm
6. Age-structured populations
In this section we extend the models 1.3 and 1.4 to accommodate age struc-
ture into the population mixing and epidemiology parameters. The incubation
period for children is shorter than that of adults. Within the adult popula-
tion there could be variability due to age at the time of infection. There are
studies that analyze the HIV data on age collected at the time of infection to
study parameters like incubation period [5], and some studies incorporate age
structure in the models to explain the impact of an age-dependent incubation
period [10]. Information on population age structure is important source of
data in a country with severe AIDS epidemic. Countries with high number of
young adults and with high-risk behavior need special interventions in terms
of behavioral counseling, treatment of drugs, monitoring and evaluation of the
epidemic. For most of the countries with high numbers of HIV infected in-
dividuals, age-related data for measuring impact of drugs are not available.
Virus transmission rates, disease progression rates and mortality rates could
be highly age-dependent. Improving surveillance activities by age-structure of
the HIV infected and susceptible populations would benefit the overall disease
control programs in a country. In the absence of availability of cohort data, the
methods explained in section 2 could be of great use to estimate the incubation
period. The analysis and method explained there could be carried out based
on the data available for individuals of every age (rounded to closest integer).
We describe the age-structure model and the method to obtain the incubation
period in this section by considering j age groups. In a hospital set-up it is
relatively easy to follow cohorts of age groups compared to following cohorts
of individuals for each age group.
Suppose the population in the jth age group is divided into Xj susceptible,
Y0,j, Y1,j, Y2,j, Y3,j are infected and Dz0,j, Dz1,j, Dz2,j, Dz3,j individuals with
the disease without drugs, and for drug1, drug2, drug3 respectively. The
differential equations explaining these variables are
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dXj
dt
= Λj −
(
λ0jk + λ
1
jk + λ
2
jk + λ
3
jk + µj
)
Xj ,
dY0,j
dt
= λ0jkXj −
{(∫
R
z0,jdG(z0,j)
)−1
+ µj
}
Y0,j,
dY1,j
dt
= λ1jkXj −
{(∫
R
z1,jdG(z1,j)
)−1
+ µj
}
Y1,j,
dY2,j
dt
= λ2jkXj −
{(∫
R
z2,jdG(z2,j)
)−1
+ µj
}
Y2,j,
dY3,j
dt
= λ3jkXj −
{(∫
R
z3,jdG(z3,j)
)−1
+ µj
}
Y3,j,
dDz0,j
dt
=
(∫
R
z0,jdG(z0,j)
)−1
Y0,j − γ0,jDz0,j
dDz1,j
dt
=
(∫
R
z1,jdG(z1,j)
)−1
Y1,j − γ1,jDz1,j(6.1)
dDz2,j
dt
=
(∫
R
z2,jdF (z2,j)
)−1
Y2,j − γ2,jDz2,j
dDz3,j
dt
=
(∫
R
z3,jdG(z3,j)
)−1
Y3,j − γ3,jDz3,j.
Here, Λj is the input of susceptibles for the individuals in the age group
j, µj is the mortality rate, λ
0
jk,λ
1
jk ,λ
2
jk and λ
3
jk are the forces of infection at
which a susceptible in the age group j is infected by an infected individual in
the age group k andγ0,j, γ1,j, γ2,j and γ3,j are disease related mortality rates
for the infected individuals in the age group j without drugs, and with drug1,
drug2, and drug3 for the individuals.
(∫
R
zi,jdG(zi,j)
)−1
is the rate of disease
progression for the infected individual for the age group j for the drug type i.
Special attention is necessary in data collection for understanding the forces
of infection by age group.
If there are n drug types available then the general model describing the
dynamics of various variables described above is as follows:
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dXj
dt
= Λj −
(
λ0jk + λ
1
jk + λ
2
jk + λ
3
jk + µj
)
Xj,
dY0,j
dt
= λ0jkXj −
{(∫
R
z0,jdG(z0,j)
)−1
+ µj
}
Y0,j,
...
...
...
...
dYn,j
dt
= λnjkXj −
{(∫
R
zn,jdG(zn,j)
)−1
+ µj
}
Yn,j,
dDz0,j
dt
=
(∫
R
z0,jdG(z0,j)
)−1
Y0,j − γ0,jDz0,j,
...
...(6.2)
...
...
dDzn,j
dt
=
(∫
R
zn,jdG(zn,j)
)−1
Yn,j − γn,jDzn,j.
where αi,j is the mortality rate of infected individuals of drug type i in the
age group j.
6.1. Varying incubation periods for age-structured populations. We
are interested in the average incubation period for a group of individuals in the
age group j. If H(j) is the time of infection and Z(j) is the incubation period
for the jth age group, then the time of onset of the disease for this age group is
D(j) = H(j) + Z(j). This is the time of onset of the disease for an individual
who acquired the infection while in the jth age group. Development of the
disease will be some time units (for example: months, years) after infection at
age j. An individual who acquired the infection at age j is assumed to develop
the full disease before completion of the same age j or > j. Given H(j),
for some j, then D(j) is allowed to occur at age j′(j′ = j, j + 1, · · · , j + ω,
where j + ω is the last age group for the possibility of infection). Clearly,
H(j) ≤ D(j). H(j) = D(j) is possible if an individual acquired infection
and attains disease before completion of age j. One can do analysis using a
bi-annual (or half-yearly) aging process.
Consider an infection and disease development matrix (see figure 6.1) where
each cell (j, j′) denotes the (infection age groups, disease onset age groups) for
j = 0, 1, 2, ..., j + ω; j′ = 0, 1, 2, ..., j + ω. Only those cells for which j ≤ j′ are
provided, and other cells are left blank for which the incubation period is not
defined. In the matrix, all the eligible cells are denoted, so obviously there are
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(0,0)          (0,1)                . . .              (0,j)            (0,j+1)                 . . .                     (0,j+w)
                   (1,1)                . . .              (1,j)            (1,j+1)                 . . .                     (1,j+w)
(j,j)            (j,j+1)                   . . .                    (j,j+w)
(j+1,j+1)               . . .                   (j+1,j+w)
(j+w,j+w)
.
.
.
.
.
.
.
.
.
.
.
.
H(j)
D(j)
0
1
.
.
.
j
j+1
.
.
.
j+w
    0                 1                 . . .                 j                j+1                      . . .                       j+w
Figure 6.1. Age-structured infection and disease development
matrix. Here row values indicate infection age group (H(j)) and
column values for age group in which infected individual devel-
oped disease (D(j)). An individual who acquired the infection
in j, and developed disease in j + ω, is indicated by the cell
(j, j + ω).
more cells present where the condition j ≤ j′ is satisfied, and also j is very
low. (In fact, the average incubation period is not beyond a certain duration.
It is not intended in the matrix to suggest that the lower the value of j then
the larger the value of incubation period). If the age of infection is higher, for
some j, and towards the last few possible age groups, then it is possible that
j′−j is shorter because individuals die naturally in old age. At the same time,
the chance of infection in the very higher age groups (say 60+) is negligible for
HIV (unless there are some rare causes). In the absence of age specific cohorts
of infected individuals and follow-up data, it is not feasible to calculate disease
progression rates and survival probabilities using direct cohort methods. In
this section, we extend the method given in section 2 to estimate the average
disease progression rates (or average incubation periods) for infections in age
group j. This method is dependent on infection densities and data on disease
occurrences for the age group j.
Let p(t, j) and q(t, j) be the probability density functions of infection density
and incubation period for the age group j. If Q(t, j) is the distribution function
of the incubation period, then Q(t, j) =
∫ t
−∞ q(t, j)dt. Now, the convolution of
p(t, j) and Q(t, j) is given by
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C(s, t) =
∫ ∞
−∞
p(t, j)Q(t− s, j)ds.
We call C the convolution of p and Q (i.e. p ∗Q, where ∗ is the convolution
operator). Therefore,
p ∗Q =
∫ ∞
−∞
p(t, j)Q(t− s, j)ds.
Suppose an individual is diagnosed with a disease at age j in the year Uk.
Then there is a possibility that this individual acquired the infection in any
of the years prior to Uk (provided this individual is born in the year ≥ U0).
Similarly, all those individuals who are diagnosed with the disease at age j+w
in the year Un have actually acquired infection in any of the years from U0 to
Un. In the same way, an individual infected at age j will be diagnosed with
the disease in an age group ≥ j. We consider model (6.1), where four types of
drugs were considered in section 2.
Let A0(j),A1(j), A2(j),A3(j) be the parameter sets in age group j for the
four kind of drugs. Let B0(j),B1(j), B2(j),B3(j) be the parameter sets C and
E0(j),E1(j), E2(j),E3(j) be the corresponding events of diagnosis of disease
in the age group j for the four types of drugs. The cumulative number of
diagnosed disease cases up to Un for individuals who are diagnosed in the age
group j is
J(U0 < s < Un, j) =
j∑
j∗=0
I(j∗, j),
where I(0, j), I(1, j), ..., I(j, j) are the numbers of disease cases diagnosed
in age group j, and acquired the infection in the age group 0, 1, ..., j.
I(0, j) =
∫ Un−k
0
p(t, 0)Q(t− s, j)ds+
∫ Un−l
Un−k
p(t, 0)Q(t− s, j)ds
+
∫ Un−m
Un−l
p(t, 0)Q(t− s, j)ds+
∫ Un
Un−m
p(t, 0)Q(t− s, j)ds
=
∫ Un−k
0
p(t, 0/A0)Q(t− s, j/B0)ds+
∫ Un−l
Un−k
p(t, 0/A1)Q(t− s, j/B1)ds
+
∫ Un−m
Un−l
p(t, 0/A2)Q(t− s, j/B2)ds+
∫ Un
Un−m
p(t, 0/A3)Q(t− s, j/B3)ds
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I(1, j) =
∫ Un−k
0
p(t, 1)Q(t− s, j)ds+
∫ Un−l
Un−k
p(t, 1)Q(t− s, j)ds
+
∫ Un−m
Un−l
p(t, 1)Q(t− s, j)ds+
∫ Un
Un−m
p(t, 1)Q(t− s, j)ds
=
∫ Un−k
0
p(t, 1/A0)Q(t− s, j/B0)ds+
∫ Un−l
Un−k
p(t, 1/A1)Q(t− s, j/B1)ds
+
∫ Un−m
Un−l
p(t, 1/A2)Q(t− s, j/B2)ds+
∫ Un
Un−m
p(t, 1/A3)Q(t− s, j/B3)ds
...
I(j, j) =
∫ Un−k
0
p(t, j)Q(t− s, j)ds+
∫ Un−l
Un−k
p(t, j)Q(t− s, j)ds
+
∫ Un−m
Un−l
p(t, j)Q(t− s, j)ds+
∫ Un
Un−m
p(t, j)Q(t− s, j)ds
=
∫ Un−k
0
p(t, j/A0)Q(t− s, j/B0)ds+
∫ Un−l
Un−k
p(t, j/A1)Q(t− s, j/B1)ds
+
∫ Un−m
Un−l
p(t, j/A2)Q(t− s, j/B2)ds+
∫ Un
Un−m
p(t, j/A3)Q(t− s, j/B3)ds
Similarly for unstructured populations, we assume that Un−k is the time
of the introduction of drugs after the first year of detection of the disease in
U0. If E1(j) ∈ [Un−k, Un−l) and E2(j) ∈ [Un−l, Un−m), then Z1(j) < Z2(j),
otherwise if E2(j) ∈ [Un−k, Un−l) and E1(j) ∈ [Un−l, Un−m) then Z2(j) <
Z1(j). If E1(j), E2(j) ∈ [Un−k, Un−m), then Z1(j) = Z2(j). Given an individual
who was diagnosed with the disease in the age group j before Un is already
developed in one of the four intervals [U0, Un−k), [Un−k, Un−l), [Un−l, Un−m)
and [Un−m, Un). If E0(j) ∈ [Ui′−1, Ui′) ⊆ [U0, Un−k), (for drug type i′), then the
conditional probability of occurrence of E0(j) given E(j) is
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Pr [E0(j)/E(j)] = Pr [Ui′−1 ≤ J ≤ Ui′ , j/J ≤ Un]
=
J [A0(j), B0(j)/Ui′, j]− J [A0(j), B0(j)/ui′−1, j]
J [A0(j), B0(j)/Un, j]
,
where J values for E0(j) are given by:
J [A0(j), B0(j)/Ui′ , j] =
∫ Ui′
0
p(t, 0/A0)Q(t− s, j/B0)ds
+
∫ Ui′
0
p(t, 1/A0)Q(t− s, j/B0)ds · · · +
∫ Ui′
0
p(t, j/A0)Q(t− s, j/B0)ds
J [A0(j), B0(j)/Ui′−1, j] =
∫ Ui′−1
0
p(t, 0/A0)Q(t− s, j/B0)ds
+
∫ Ui′−1
0
p(t, 1/A0)Q(t− s, j/B0)ds · · · +
∫ Ui′−1
0
p(t, j/A0)Q(t− s, j/B0)ds
J [A1(j), B1(j)/Un, j] =
∫ Un
0
p(t, 0/A0)Q(t− s, j/B0)ds
+
∫ Un
0
p(t, 1/A0)Q(t− s, j/B0)ds · · · +
∫ Un
0
p(t, j/A0)Q(t− s, j/B0)ds
The above probability expressions are for the case without drug interven-
tions. When drugs were initiated at Un−k, then these probabilities changed
according to the occurrence of E1(j), E2(j), E3(j). Suppose E1(j)∩E2(j) = ∅.
If [Uk′−1, Uk′) ⊆ [Un−k, Un−l), and E1 ∈ [Un−k, Un−l), then
Pr [E1(j)/E(j)] = Pr [Uk′−1 ≤ J ≤ Uk′, j/J ≤ Un]
=
J [A1(j), B1(j)/Uk′, j]− J [A1(j), B1(j)/uk′−1, j]
J [A1(j), B1(j)/Un, j]
,
where J values for E1(j) are given by
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J [A1(j), B1(j)/Uk′, j] =
∫ Uk′
0
p(t, 0/A1)Q(t− s, j/B1)ds
+
∫ Uk′
0
p(t, 1/A1)Q(t− s, j/B1)ds · · · +
∫ Uk′
0
p(t, j/A1)Q(t− s, j/B1)ds
J [A1(j), B1(j)/Uk′−1, j] =
∫ Uk′−1
0
p(t, 0/A1)Q(t− s, j/B1)ds
+
∫ Uk′−1
0
p(t, 1/A1)Q(t− s, j/B1)ds · · · +
∫ Uk′−1
0
p(t, j/A1)Q(t− s, j/B1)ds
J [A1(j), B1(j)/Un, j] =
∫ Un
0
p(t, 0/A1)Q(t− s, j/B1)ds
+
∫ Un
0
p(t, 1/A1)Q(t− s, j/B1)ds · · · +
∫ Un
0
p(t, j/A1)Q(t− s, j/B1)ds
In the above, instead of E1(j), if E2 ∈ [Un−k, Un−l), then the probabilities
would be
Pr [E2(j)/E(j)] = Pr [Uk′−1 ≤ J ≤ Uk′, j/J ≤ Un]
=
J [A2(j), B2(j)/Uk′, j]− J [A2(j), B2(j)/uk′−1, j]
J [A2(j), B2(j)/Un, j]
,
where J values for E1(j) are given by
J [A2(j), B2(j)/Uk′, j] =
∫ Uk′
0
p(t, 0/A2)Q(t− s, j/B2)ds
+
∫ Uk′
0
p(t, 1/A2)Q(t− s, j/B2)ds · · · +
∫ Uk′
0
p(t, j/A2)Q(t− s, j/B2)ds
J [A2(j), B2(j)/Uk′−1, j] =
∫ Uk′−1
0
p(t, 0/A2)Q(t− s, j/B2)ds
+
∫ Uk′−1
0
p(t, 1/A2)Q(t− s, j/B2)ds · · · +
∫ Uk′−1
0
p(t, j/A2)Q(t− s, j/B2)ds
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J [A2(j), B2(j)/Un, j] =
∫ Un
0
p(t, 0/A2)Q(t− s, j/B2)ds
+
∫ Un
0
p(t, 1/A2)Q(t− s, j/B2)ds +
∫ Un
0
p(t, j/A2)Q(t− s, j/B2)ds
If [Ul−1, Ul) ⊆ [Un−l, Un−m), and E1 ∈ [Un−l, Un−m), then
Pr [E1(j)/E(j)] = Pr [Ul′−1 ≤ J ≤ Ul′, j/J ≤ Un]
=
J [A1(j), B1(j)/Ul′, j]− J [A1(j), B1(j)/ul′−1, j]
J [A1(j), B1(j)/Un, j]
,
where J values for E1(j) are given by
J [A1(j), B1(j)/Ul′ , j] =
∫ Ul′
0
p(t, 0/A1)Q(t− s, j/B1)ds
+
∫ Ul′
0
p(t, 1/A1)Q(t− s, j/B1)ds · · · +
∫ Ul′
0
p(t, j/A1)Q(t− s, j/B1)ds
J [A1(j), B1(j)/Ul′−1, j] =
∫ Ul′−1
0
p(t, 0/A1)Q(t− s, j/B1)ds
+
∫ Ul′−1
0
p(t, 1/A1)Q(t− s, j/B1)ds · · · +
∫ Ul′−1
0
p(t, j/A1)Q(t− s, j/B1)ds
J [A1(j), B1(j)/Un, j] =
∫ Un
0
p(t, 0/A1)Q(t− s, j/B1)ds
+
∫ Un
0
p(t, 1/A1)Q(t− s, j/B1)ds · · · +
∫ Un
0
p(t, j/A1)Q(t− s, j/B1)ds
Suppose [Ul−1, Ul) ⊆ [Un−l, Un−m), and E2 ∈ [Un−l, Un−m) then
Pr [E2(j)/E(j)] = Pr [Ul′−1 ≤ J ≤ Ul′ , j/J ≤ Un]
=
J [A2(j), B2(j)/Ul′ , j]− J [A2(j), B2(j)/ul′−1, j]
J [A2(j), B2(j)/Un, j]
where J values for E2(j) are given as below:
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J [A2(j), B2(j)/Ul′ , j] =
∫ Ul′
0
p(t, 0/A2)Q(t− s, j/B2)ds
+
∫ Ul′
0
p(t, 1/A2)Q(t− s, j/B2)ds · · · +
∫ Ul′
0
p(t, j/A2)Q(t− s, j/B2)ds
J [A2(j), B2(j)/Ul′−1, j] =
∫ Ul′−1
0
p(t, 0/A2)Q(t− s, j/B2)ds
+
∫ Ul′−1
0
p(t, 1/A2)Q(t− s, j/B2)ds · · · +
∫ Ul′−1
0
p(t, j/A2)Q(t− s, j/B2)ds
J [A2(j), B2(j)/Un, j] =
∫ Un
0
p(t, 0/A2)Q(t− s, j/B2)ds
+
∫ Un
0
p(t, 1/A2)Q(t− s, j/B2)ds · · · +
∫ Un
0
p(t, j/A2)Q(t− s, j/B2)ds
If E1(j) = E2(j) ∈ [Up′−1, Up′) ⊆ [Un−k, Un−m) i.e. Z1(j) = Z2(j), then the
conditional probabilities contain the same parameter sets. The probabilities
for this situation are
Pr [E1(j) = E2(j)/E(j)] = Pr [Up′−1 ≤ J ≤ Up′, j/J ≤ Un]
=
J [A2(j), B2(j)/Up′, j]− J [A2(j), B2(j)/up′−1, j]
J [A2(j), B2(j)/Un, j]
,
where J values for E2(j) are given by
J [A2(j), B2(j)/Up′, j] =
∫ Up′
0
p(t, 0/A2)Q(t− s, j/B2)ds
+
∫ Up′
0
p(t, 1/A2)Q(t− s, j/B2)ds · · · +
∫ Up′
0
p(t, j/A2)Q(t− s, j/B2)ds
J [A2(j), B2(j)/Up′−1, j] =
∫ Up′−1
0
p(t, 0/A2)Q(t− s, j/B2)ds
+
∫ Up′−1
0
p(t, 1/A2)Q(t− s, j/B2)ds · · · +
∫ Up′−1
0
p(t, j/A2)Q(t− s, j/B2)ds
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J [A2(j), B2(j)/Un, j] =
∫ Un
0
p(t, 0/A2)Q(t− s, j/B2)ds
+
∫ Un
0
p(t, 1/A2)Q(t− s, j/B2)ds · · · +
∫ Un
0
p(t, j/A2)Q(t− s, j/B2)ds
Since Z3(j) > {Z0(j), Z1(j), Z2(j)}, suppose E3(j) ∈ [Um′−1, Um′) ⊆ [Un−m, Un],
now above probabilities are
Pr [E3(j)/E(j)] = Pr [Um′−1 ≤ J ≤ Um′ , j/J ≤ Un]
=
J [A3(j), B3(j)/Um′ , j]− J [A3(j), B3(j)/um′−1, j]
J [A3(j), B3(j)/Un, j]
where J values for E3(j) are given by
J [A3(j), B3(j)/Um′ , j] =
∫ Um′
0
p(t, 0/A3)Q(t− s, j/B3)ds
+
∫ Um′
0
p(t, 1/A3)Q(t− s, j/B3)ds · · · +
∫ Um′
0
p(t, j/A3)Q(t− s, j/B3)ds
J [A3(j), B3(j)/Um′−1, j] =
∫ Um′−1
0
p(t, 0/A3)Q(t− s, j/B3)ds
+
∫ Um′−1
0
p(t, 1/A3)Q(t− s, j/B3)ds · · · +
∫ Um′−1
0
p(t, j/A3)Q(t− s, j/B3)ds
J [A3(j), B3(j)/Un, j] =
∫ Un
0
p(t, 0/A3)Q(t− s, j/B3)ds
+
∫ Un
0
p(t, 1/A3)Q(t− s, j/B3)ds · · · +
∫ Un
0
p(t, j/A3)Q(t− s, j/B3)ds
Using the above conditional probabilities, likelihood functions are constructed
by assuming some parametric form for the diagnosed disease cases. For each
age group above, analysis is conducted to estimate the incubation periods by
age group.
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7. Conclusions
The methods and models developed support further biological and epidemi-
ological experiments in the HIV infected population. As per the current WHO
guidelines, ART is prescribed only when CD4 count reaches 250. Experiments
indicate mortality rate among HIV infected population drops after individ-
uals are on ART, and hence expected life years remaining once individuals
reaches CD4 = 250 is different for those individuals who are on ART and who
are not on ART. After providing ART for all the eligible people, the length
of life gained by individuals can be measured and resultant functional form
can be modeled. Similarly, a model can be built for lengths of lives for those
individuals who reach CD4=250 and not on ART.
The improved models that address the impacts of anti-retroviral therapy,
protease inhibitors and combination of drugs presented in section 1 seem use-
ful in understanding the dynamics of variables for individuals with the full
blown disease for no-drug, drug1, drug2 and drug3, i.e Dz0 , Dz1, Dz2and Dz3 .
Using the methodology in sections 2 to 4, (despite being lengthy), one can
able to estimate the parameters for the incubation period for each drug type,
by the deconvolution method. We have demonstrated this method for three
types of drugs, and one can obtain B for as many drugs as possible from the
formulas for n−types of drugs in section 3. So far, there is no evidence of
drugs being useful in avoiding contracting the disease. Drugs may be useful
for avoiding opportunistic infections for some specific periods of time. Eventu-
ally, an individual will succumb to AIDS, whether or not that individual takes
drugs (which is also demonstrated in the truncation effect in Figure 9.1). The
truncation effect formulas can be used to obtain the parameter set (say, BT ),
but we did not demonstrate this numerically. There were other type of meth-
ods for obtaining incubation periods (see [18] when data is censored and see
[48] when data is from hospital based cohort)
We did not introduce intracellular delay that might arise due drug interven-
tions. There are not many quantitative results available on the relationship
between the dose of a drug and the resultant delay in the development of
the disease. Suppose s1, s2, s3..., sk are k levels of doses of a single drug, and
τ1, τ2, τ3, ..., τk are the respective delays obtained in producing a new infected
cell. Then we can write the relation R2 (s, τ) between s and τ as
{∑k
i=1 (si − s) (τi − τ)
}2
{∑k
i=1 (si − s)
}2 {∑k
i=1 (τi − τ )
}2
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R2 (s, τ) is called the correlation coefficient of dose-delay. s is the mean
dose-level and τ is the mean delay. This experiment can be conducted for
various doses sij (say) for drug type j = 1, 2, 3...n. Each drug will produce
a delay depending upon the dose level. From this, the average delay can be
statistically compared to understand the mean dose effect due to a particular
drug, and hence the drug efficacy. However, this does not give dynamics over
the time period, but it is very useful in preparing the baseline parameters for
simulation studies, and also for the models explained in sections 1, 2 and 5.
There might be a possibility of exploring the impact of delay in the conditional
probabilities expressed in this work.
Our work may be interesting for people working on developing computa-
tional techniques for solving integro-differential equations, algorithms to solve
convolution type equations in epidemiology, and EM-type algorithms. The
age-structure analysis presented is more complicated than analysis presented
for the non-age structured populations, and we provide a new kind of analysis
for the incubation period. When reported disease cases and densities of the
infection are available for a period of several years in the population, then
this kind of analysis offers a reliable method to estimate the incubation period
distribution.
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8. Appendix I : Conditional probabilities for generalized
multiple drug impact
Here we derive expressions for conditional probabilities when several drugs
are available, and the incubation period is non-monotonic. When such a sit-
uation arises there will be several combinations of orders of Zs. We take one
such situation and write corresponding Ls for the purpose of demonstration.
Suppose Z0 < ... < Zk = ... = Zk+n+1 < ... < ZN . Let us divide this into the
following two inequalities and an equality: Z0 < ... < Zk , Zk+1 = ... = Zk+n
and Zk+n+1 < ... < ZN . If we consider the first and third inequalities, then
D (A,B/UNk) =
∫ UN0
0
h(t/AN0)G(t− s/BN0)ds+
∫ UN1
UN0
h(t/AN1)G(t− s/BN1)ds
· · ·+
∫ UNk
UNk−1
h(t/ANk)G(t− s/BNk)ds
D (A,B/UNN ) =
∫ UNn+k+1
0
h(t/ANn+k+1)G(t− s/BNn+k+1)ds+
∫ UNn+k+2
UN0
h(t/ANn+k+2)G(t− s/BNn+k+2)ds
· · ·+
∫ UNN
UNN−1
h(t/ANN )G(t− s/BNN )ds
We can express {P (ENθ/E)}θ=kθ=0 and {P (ENθ/E)}θ=Nθ=n+k+1 and the correspond-
ing {LNθ}θ as shown in the section 3. Then LNθ is maximized for the set
[Aθ, Bθ]. We obtain N − n − k sets of [A,B] values, and the corresponding
likelihood functions {LNθ}kθ=0 and {LNθ}Nθ=n+k+1
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Time 
1.0
0.5
0.0
Figure 9.1. Truncated incubation period. The idea of trun-
cated cumulative distribution of the incubation period is plot-
ted. After a certain time duration, there will not be any gain
due to therapy. Median incubation period is represented by the
line cutting the curve at 0.5, corresponding to the Y-axis.
9. Appendix II: Truncated incubation period
Suppose there is an upper bound for the impact of drugs on the incubation
period; that is, the incubation period cannot be increased after a certain time
point after the drug use. Then the likelihood equations explained in section
4 would change accordingly. There was an attempt earlier to truncate the
incubation period with the help of the truncated Weibull distribution [17].
They have not seen the impact of drugs using such functions. If Z, the length
of the incubation period, and if Zc is the truncation point, then G(Z) =
1 − exp
{
−
(
z
δ1
)δ2}
, for 0 < Z < Zc, and G(Z) = 1 − exp
{
−
(
z
δ1
)δ2}
exp
{
−
(
δ2
δ1
)(
tc
δ1
)(δ2−1)(z−zc)}
, for Z ≥ Zc. Here, δ1, δ2 are scale and shape
parameters. One can construct a likelihood function for each drug type using
such functions as follows:
L (A,B/Pj) = L<Zc + L≥Zc ,(9.1)
where
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L<Zc =
∏
j
b1(j)b2(j)−
∏
j
b1(j − 1)b2(j)
L≥Zc =
∏
j
bt1(j)b
t
2(j)−
∏
j
bt1(j − 1)bt2(j)
and
b1(j) =
{∫ uj
0
eα1s
2+α2s+α3
{
1− exp
{
−
(
t
δ1
)δ2}}
ds
}Tj
b1(j − 1) =
{∫ uj−1
0
eα1s
2+α2s+α3
{
1− exp
{
−
(
t
δ1
)δ2}}
ds
}Tj
b2(j) =
{∫ un
0
eα1s
2+α2s+α3
{
1− exp
{
−
(
t
δ1
)δ2}}
ds
}−Tj
bt1(j) =
[∫ uj
0
eα1s
2+α2s+α31− exp
{
−
(
z
δ1
)δ2}
×
exp
{
−
(
δ2
δ1
)(
tc
δ1
)(δ2−1)(z−zc)}
ds
]Tj
bt1(j − 1) =
[∫ uj−1
0
eα1s
2+α2s+α31− exp
{
−
(
z
δ1
)δ2}
×
exp
{
−
(
δ2
δ1
)(
tc
δ1
)(δ2−1)(z−zc)}
ds
]Tj
bt2(j) =
[∫ un
0
eα1s
2+α2s+α31− exp
{
−
(
z
δ1
)δ2}
×
exp
{
−
(
δ2
δ1
)(
tc
δ1
)(δ2−1)(z−zc)}
ds
]
.−Tj
For each drug type, an expression of the type in (9.1) can be derived. Despite
the assumption on truncation as mentioned above, the incubation period could
vary according to the type of the drug.
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Table 1. Parameters
10. APPENDIX III : Parameters
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11. APPENDIX IV: FIGURES
In this section using the parameters in the Appendix III, output of the
models for hypothetical population sizes and sensitivity of the parameters in
projecting HIV and AIDS are shown through Figure 11.1 to Figure 11.5.
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(a)
(b)
(c)
Figure 11.1. (a) Number of HIV and AIDS (before therapy),
(b) Number of HIV infected (before therapy), (c) Number of
HIV (after therapy)
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(a)
(b)
(c)
Figure 11.2. (a) Sensitivity of d0 on Y0, (b) Sensitivity of d1
and d2 on Y1 and Y2, (c) Sensitivity of d3 on Y3.
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Figure 11.3. (a) Sensitivity of d0 on Dz0, (b) Sensitivity of d1
and d2 on Dz1 and Dz2, (c) Sensitivity of d3 on Dz3.
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Figure 11.4. (a) Sensitivity of γ0 on Dz0, (b) Sensitivity of γ1
and γ2 on Dz1 and Dz2, (c) Sensitivity of γ3 on Dz3.
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Figure 11.5. (a) Sensitivity of λ0 on Dz0, (b) Sensitivity of λ1
and λ2 on Dz1 and Dz2, (c) Sensitivity of λ3 on Dz3.
